Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Hits Expectations

Key Points

• Cogent Biosciences reported quarterly EPS of ($0.53), matching consensus, while its shares trade around $36.97 with a market cap of $6.31 billion and a negative P/E.
• Analyst sentiment is mostly positive with a “Moderate Buy” consensus and an average target of $43.45, and several firms issuing higher targets (Jefferies $55; HC Wainwright and Piper Sandler $52) despite a few cautious downgrades.
• Cogent is a clinical‑stage biopharma developing an oral CSF1R inhibitor to modulate the tumor microenvironment, with its lead asset in early‑stage trials for solid tumors.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) issued its earnings results on Tuesday. The technology company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53), FiscalAI reports.

Cogent Biosciences Price Performance

COGT stock opened at $36.97 on Wednesday. Cogent Biosciences has a 1 year low of $4.55 and a 1 year high of $43.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 14.23 and a current ratio of 14.23. The stock's 50 day moving average price is $36.46 and its 200 day moving average price is $34.55. The firm has a market cap of $6.31 billion, a P/E ratio of -17.12 and a beta of 0.37.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on COGT. Jefferies Financial Group began coverage on Cogent Biosciences in a research note on Monday, March 16th. They issued a "buy" rating and a $55.00 price target on the stock. Robert W. Baird set a $35.00 price objective on Cogent Biosciences in a research report on Thursday, February 19th. HC Wainwright raised their target price on Cogent Biosciences to $52.00 and gave the company a "buy" rating in a report on Tuesday, January 6th. Piper Sandler boosted their target price on shares of Cogent Biosciences from $39.00 to $52.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Finally, Wall Street Zen downgraded shares of Cogent Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, January 31st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $43.45.

Hedge Funds Weigh In On Cogent Biosciences

Institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. boosted its stake in shares of Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company's stock valued at $33,000 after acquiring an additional 1,333 shares during the last quarter. Strs Ohio acquired a new position in Cogent Biosciences in the 1st quarter valued at about $36,000. Global Retirement Partners LLC acquired a new position in Cogent Biosciences in the 4th quarter valued at about $37,000. PNC Financial Services Group Inc. lifted its holdings in Cogent Biosciences by 414.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company's stock valued at $46,000 after purchasing an additional 1,032 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Cogent Biosciences by 16.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company's stock worth $77,000 after purchasing an additional 300 shares during the last quarter.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.